Hainan Poly Pharm’s Generic Ganciclovir Approved in Denmark
China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced receiving marketing approval from the...
Jacobio Pharma Doses First Patient in US Phase I/IIa Study for JAB-2485
China-based Jacobio Pharma (HKG: 1167) has announced that the first patient has been dosed in...
VACSERA in Talks with Sinovac to Establish Integrated Vaccine Plant
Egypt-based drug firm Holding Company for Biological Products and Vaccines (VACSERA) is reportedly in talks...
Eisai CEO Outlines Ambitions for Alzheimer’s Drug Leqembi After FDA Approval
Following US FDA approval for Japan-based Eisai Co., Ltd (TYO: 4523) and Biogen Inc’s (NASDAQ:...
Dizal’s Sunvozertinib and Golidocitinib Combo Gets NMPA Approval for Phase II Study
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced receiving approval from the National Medical...
Luye Pharma’s BA1301 Receives CDE Approval for Clinical Trials
China-based Luye Pharma Group (HKG: 2186) has announced receiving clinical trial approval from the Center...
China’s National Health Commission Releases Updated COVID-19 Treatment Plan
The National Health Commission (NHC) has released the 10th edition of the national COVID-19 Diagnosis...
HutchMed’s Sovleplenib Administered to First Patient in Phase II COVID-19 Study
On January 4, Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) administered its novel, investigational,...
Zai Lab and Novocure’s TTFields Device Shows Survival Benefit in Lung Cancer Study
Shares in Chinese firm Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) and its partner Novocure...
Salubris Pharmaceuticals Gains NMPA Approval for Phase I Study of SAL0133
China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) has announced receiving approval from the National...
Kactus Biosystems Partners with Bioheng for Cell Therapy Raw Materials
Shanghai-based Kactus Biosystems, a firm specializing in target proteins and raw enzymes, has announced a...
Immune-Onc Therapeutics Completes $131 Million Series B Financing
US-headquartered Immune-Onc Therapeutics, Inc. has announced the successful completion of a Series B financing round...
Henlius Completes First Dosing in Global Phase III Study for HanSiZhuang in LS-SCLC
Shanghai Henlius Biotech (HKG: 2696) has announced the completion of the first subject dosing in...
Singular Medical Secures Series B+ Funding for Cardiac Device Development
Singular Medical, a Suzhou-based maker of cardiac rhythm and heart failure devices, has reportedly raised...
Boehringer Ingelheim Enrolls First Patient in Phase II/III Study for BI 907828
German pharmaceutical giant Boehringer Ingelheim has announced the enrollment of the first patient in the...
Vcanbio’s Stem Cell Therapy VUM02 Accepted for Clinical Trial Review
China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that the clinical...
CanSino Biologics’ mRNA Vaccine CS-2034 Shows Positive Safety and Immunogenicity Data
China-based CanSino Biologics (HKG: 6185) has announced positive periodical data from a clinical study assessing...
Mindray Partners with BOMImed for Exclusive Canadian Sales and Service
China-based medical device giant Mindray’s North American unit has announced a partnership with Canadian biomedical...
Simnova Partners with Orna Therapeutics for In Situ CAR Therapies
Shanghai Simnova Biotech Co., Ltd. (Simnova), an affiliate of Simcere Investment Group, has announced a...
Aurisco Partners with Cytiva to Build Oligonucleotide Production Plant
China-based contract development and manufacturing organization (CDMO) Aurisco Pharmaceutical Co., Ltd has revealed plans to...